Skip to main content

Month: July 2025

Orion Group Holdings Reports Second Quarter 2025 Results and Reaffirms Fiscal Year 2025 Guidance

HOUSTON, July 29, 2025 (GLOBE NEWSWIRE) — Orion Group Holdings, Inc. (NYSE: ORN) (the “Company”, “Orion”), a leading specialty construction company, today reported its financial results for the second quarter ended June 30, 2025. Highlights for the quarter ended June 30, 2025: (Comparisons to second quarter of 2024) ($ in millions, except EPS)Revenue grew 7% to $205 million GAAP Net Income grew $7.4 million to $0.8 million Adjusted EBITDA doubled to $11 million and margins increased 240 bps to 5.3% Contracted backlog at the end of 2Q2025 was $750 million with 1H’25 new contract wins of over $450 million Management reaffirmed full year 2025 guidance Strengthened management team by adding Alison Vasquez, CFO, to help execute the next phase of the Company’s growth strategy  Three months ended  June 30,   June 30,  2025   2024Revenue $ 205.3   $ 192.2  GAAP...

Continue reading

Teladoc Health Reports Second Quarter 2025 Results

NEW YORK, July 29, 2025 (GLOBE NEWSWIRE) — Teladoc Health, Inc. (NYSE: TDOC), the global leader in virtual care, today reported financial results for the three months ended June 30, 2025 (“Second Quarter 2025”). Unless otherwise noted, percentage and other changes are relative to the three months ended June 30, 2024 (“Second Quarter 2024”). HighlightsSecond Quarter 2025 revenue of $631.9 million, down 2% year-over-year Second Quarter 2025 net loss of $32.7 million, or $0.19 per share Second Quarter 2025 adjusted EBITDA of $69.3 million, down 23% year-over-year Integrated Care segment revenue of $391.5 million, up 4% year-over-year, and adjusted EBITDA margin of 14.7% BetterHelp segment revenue of $240.4 million, down 9% year-over-year, and adjusted EBITDA margin of 4.9% Paid $550.6 million using cash on hand to retire convertible...

Continue reading

Varonis Announces Second Quarter 2025 Financial Results

Annual recurring revenues grew 19% year-over-yearSaaS ARR as a percentage of total ARR was approximately 69%Year-to-date cash from operations generated $89.3 million vs. $68.4 million last yearYear-to-date free cash flow generated $82.7 million vs. $67.3 million last year MIAMI, July 29, 2025 (GLOBE NEWSWIRE) — Varonis Systems, Inc. (Nasdaq: VRNS), the leader in data security, today announced financial results for the second quarter ended June 30, 2025. Yaki Faitelson, Varonis CEO, said, “We are excited by the many tailwinds we are seeing in our business. The simplicity and automated outcomes of our SaaS platform and MDDR, the adoption of AI and the growing awareness for data-centric cloud and SaaS security are continuing to drive momentum in our business, and we look forward to executing on this massive and growing market...

Continue reading

CTO Realty Growth Reports Second Quarter 2025 Operating Results

– Signed 190,000 square feet of comparable leases at 22% growth in cash rent spread –– Reaffirmed 2025 Outlook – WINTER PARK, Fla., July 29, 2025 (GLOBE NEWSWIRE) — CTO Realty Growth, Inc. (NYSE: CTO) (the “Company” or “CTO”), an owner and operator of retail-based properties located primarily in higher-growth markets, today announced its operating and financial results for the quarter ended June 30, 2025. Second Quarter 2025 HighlightsNet Loss attributable to common stockholders of $(0.77) per diluted share. Core Funds from Operations (“FFO”) attributable to common stockholders, of $0.45 per diluted share. Adjusted Funds from Operations (“AFFO”) attributable to common stockholders of $0.47 per diluted share. Signed 190,027 square feet of comparable leases at a positive cash rent spread of 21.6%. Current signed-not-open pipeline...

Continue reading

Cardiff Oncology Reports Second Quarter 2025 Results and Provides Business Update

– Appointed Dr. Roger Sidhu as Chief Medical Officer – – Completed enrollment in randomized Phase 2 CRDF-004 trial evaluating onvansertib + standard of care for the treatment of first-line RAS-mutated metastatic colorectal cancer (“mCRC”) – – Announced positive data from investigator-initiated trial of onvansertib in combination with paclitaxel in mTNBC at ASCO 2025 – – Cash and investments of $71.0 million as of June 30, 2025, projected runway into Q1 2027 – – Company to hold a conference call today at 4:30 p.m. ET/1:30 p.m. PT to share updated clinical data from the CRDF-004 trial – SAN DIEGO, July 29, 2025 (GLOBE NEWSWIRE) — Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range...

Continue reading

Safe Bulkers, Inc. Reports Second Quarter 2025 Results and Declares Dividend on Common Stock

MONACO, July 29, 2025 (GLOBE NEWSWIRE) — Safe Bulkers, Inc. (the “Company”) (NYSE: SB), an international provider of marine drybulk transportation services, announced today its unaudited financial results for the three and six-month periods ended June 30, 2025. The Board of Directors (the “Board”) of the Company also declared a cash dividend of $0.05 per share of outstanding common stock.Financial highlights            In million U.S. Dollars except per share data Q2 2025 Q1 2025 Q4 2024 Q3 2024 Q2 2024 Six Months 2025 Six Months 2024Net revenues 65.7 64.3 71.5 75.9 78.5 130.1 160.2Net income 1.7 7.2 19.4 25.1 27.6 8.9 52.9Adjusted Net income1 3.0 7.8 18.1 19.0 20.3 10.7 44.5EBITDA2 24.2 28.8 41.9 47.4 49.2 53.1 97.1Adjusted EBITDA2 25.5 29.4 40.7 41.3 41.8 54.9 88.7Earnings per share...

Continue reading

Expand Energy Corporation Reports Second Quarter 2025 Results

OKLAHOMA CITY, July 29, 2025 (GLOBE NEWSWIRE) — Expand Energy Corporation (NASDAQ: EXE) (“Expand Energy” or the “Company”) today reported second quarter 2025 financial and operating results.Net cash provided by operating activities of $1,322 million Net income of $968 million, or $4.02 per fully diluted share; adjusted net income(1) of $265 million, or $1.10 per share Adjusted EBITDAX(1) of $1,176 million Produced ~7.20 Bcfe/d net (92% natural gas) Delivered the highest average drilled footage per day in all three business units Reduced full year 2025 drilling and completion capital expenditures guidance by ~$100 million to achieve ~$2.9 billion total capital expenditures Increased annual synergy outlook to $600 million by year end 2026 Announced ~$425 million of incremental free cash flow in 2025, primarily driven by improved...

Continue reading

Beta Bionics Reports Second Quarter 2025 Financial Results and Raises Full Year 2025 Guidance

IRVINE, Calif., July 29, 2025 (GLOBE NEWSWIRE) — Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, today reported its financial results for the quarter ended June 30, 2025 and raised its full year guidance for the year ending December 31, 2025. Second Quarter 2025 Financial Results & Key MetricsNet sales of $23.2 million, up 54% compared to $15.0 million in the second quarter of 2024.Durable Medical Equipment (DME) channel net sales of $18.6 million, up 31% compared to $14.3 million in the second quarter of 2024. Pharmacy Benefit Plan (PBP) channel net sales of $4.6 million, up 498% compared to $0.8 million in the second quarter of 2024.Gross margin of 53.8%, up 7 basis points compared to 53.7% in the second quarter of 2024. Installed customer base (calculated...

Continue reading

EXL Reports 2025 Second Quarter Results

2025 Second Quarter Revenue of $514.5 Million, up 14.7% year-over-year Q2 Diluted EPS (GAAP) of $0.40, up 43.9% from $0.28 in Q2 of 2024 Q2 Adjusted Diluted EPS (Non-GAAP) (1) of $0.49, up 20.3% from $0.40 in Q2 of 2024 NEW YORK, July 29, 2025 (GLOBE NEWSWIRE) — ExlService Holdings, Inc. (NASDAQ: EXLS), a global data and AI company, today announced its financial results for the quarter ended June 30, 2025. Chairman and Chief Executive Officer Rohit Kapoor said, “I am pleased to report another strong quarter as we delivered revenue growth of 15% and increased our adjusted diluted EPS by 20%. Our sustained double-digit growth demonstrates the strength of our competitive position as a global data and AI company. EXL’s recognized leadership in embedding AI in the workflow is resonating strongly with our clients and fueling our growth.” Chief...

Continue reading

Big 5 Sporting Goods Corporation Announces Fiscal 2025 Second Quarter Results

EL SEGUNDO, Calif., July 29, 2025 (GLOBE NEWSWIRE) — Big 5 Sporting Goods Corporation (Nasdaq: BGFV) (the “Company,” “we,” “our,” “us,” “Big 5”), a leading sporting goods retailer, today reported financial results for the fiscal 2025 second quarter ended June 29, 2025. Net sales were $184.9 million compared to net sales of $199.8 million for the second quarter of fiscal 2024. Same store sales decreased 6.1% for the second quarter of fiscal 2025 compared to the second quarter of fiscal 2024. Gross profit for the fiscal 2025 second quarter was $52.2 million, compared to $58.7 million in the second quarter of the prior year. The Company’s gross profit margin was 28.2% in the fiscal 2025 second quarter versus 29.4% in the second quarter of the prior year. The decrease in gross profit margin compared with the prior year primarily reflected...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.